Program
mirvetuximab soravtansine
Also written as “Mirvetuximab Soravtansine”, “Mirvetuximab soravtansine” and “TAK-853”.
Its studies are mostly in Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Fallopian Tube Neoplasms · Neoplasms, led by 5 companies.
Drug pageMirvetuximab soravtansine: every studyMany companies study it; this page follows only the 15 they lead. All 28 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 115 open or running | phase 3since Dec 10, 2015 | May 30, 2012 | Nov 2026phase 2 · NCT05456685 |
| AGO Researchits history only | 11 open or running | phase 2since Feb 10, 2020 | Feb 10, 2020 | none ahead |
| Huadong Medicineits history only | 10 open or running | phase 3since Nov 14, 2022 | Nov 14, 2022 | none ahead |
| Pheast Therapeuticsits history only | 11 open or running | phase 1since Feb 10, 2025 | Feb 10, 2025 | Apr 2029phase 1 · NCT06840886 |
| Takedaits history only | 11 open or running | phase 2since Apr 26, 2024 | Apr 26, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since May 30, 2012.
- Jun 9, 2015Named mirvetuximab soravtansineINNProposed as its International Nonproprietary Name in WHO's List 113 · before, TAK-853
- Nov 6, 2015Phase 2 study in Carcinoma, Ovarian EpithelialAbbVie · NCT02606305 · 264 enrolled · United States, Belgium, Canada and more
- Dec 10, 2015Phase 3 study in Carcinoma, Ovarian EpithelialAbbVie · NCT02631876 · 366 enrolled · United States, Belgium, Bosnia and Herzegovina and more
- Dec 17, 2019Phase 3 study in Carcinoma, Ovarian EpithelialAbbVie · NCT04209855 · 453 enrolled · United States, Australia, Belgium and more
- Feb 10, 2020AGO Research’s first study: phase 2 study in Recurrent Epithelial Ovarian, Fallopian or Peritoneal CarcinomaNew to AGO ResearchAGO Research · NCT04274426 · 136 enrolled · Germany
- Feb 27, 2020Phase 3 study in Carcinoma, Ovarian EpithelialAbbVie · NCT04296890 · 106 enrolled · United States, Australia, Belgium and more
- Aug 24, 2021Phase 2 study in Ovarian NeoplasmsAbbVie · NCT05041257 · 79 enrolled · United States, Australia, Belgium and more
- Jun 29, 2022Phase 2 study in Fallopian Tube NeoplasmsAbbVie · NCT05456685 · 125 enrolled · United States, Belgium, Canada and more
- Jun 30, 2022Phase 3 study in Ovarian NeoplasmsAbbVie · NCT05445778 · 520 enrolled · United States, Argentina, Australia and more
- Nov 14, 2022Huadong Medicine’s first study: phase 3 study in Carcinoma, Ovarian EpithelialNew to Huadong MedicineHuadong Medicine · NCT05622890 · 35 enrolled · China
- Apr 26, 2024Takeda’s first study: phase 2 study in Ovarian NeoplasmsNew to TakedaTakeda · NCT06390995 · 28 enrolled · Japan
- Nov 8, 2024Phase 2 study in Fallopian Tube NeoplasmsAbbVie · NCT06682988 · 110 planned · United States, Australia, Belgium and more
- Feb 10, 2025Pheast Therapeutics’ first study: phase 1 study in Ovarian NeoplasmsNew to Pheast TherapeuticsPheast Therapeutics · NCT06840886 · 426 planned · United States
- Mar 20, 2025Phase 2 study in Carcinoma, Ovarian EpithelialAbbVie · NCT06890338 · 140 planned · United States
- Jul 2, 2025Phase 2 study in Ovarian NeoplasmsAbbVie · NCT07059845 · 400 planned · United States, Australia, Belgium and more
Ahead
- Nov 2026Primary completion: phase 2 study in Fallopian Tube NeoplasmsAbbVie · NCT05456685
- Apr 2027Primary completion: phase 3 study in Ovarian NeoplasmsAbbVie · NCT05445778
- Jan 2029Primary completion: phase 2 study in Ovarian NeoplasmsAbbVie · NCT07059845
- Apr 2029Primary completion: phase 1 study in Ovarian NeoplasmsPheast Therapeutics · NCT06840886
TargetBeta
“An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) ”NCIt, by rule
“Folate receptor alpha binding agent”ChEMBL 37, by rule
Other programs on FOLR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rinatabart sesutecanrule | Genmab | phase 3 | 9 |
| torvutatug samrotecan | AstraZeneca | phase 3 | 5 |
| sofetabart mipitecan | Eli Lilly | phase 3 | 2 |
| opugotamig olatansine | AbbVie | phase 2 | 2 |
| Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901 | AbbVie | phase 1 | 1 |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | teneoseven-inc | phase 1 | 1 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07059845Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | AbbVie | Jan 2029 | 400 |
| NCT06890338Carcinoma, Ovarian Epithelial · United States | 2 | Recruiting | AbbVie | Feb 2030 | 140 |
| NCT06840886Ovarian Neoplasms · United States | 1 | Recruiting | Pheast Therapeutics | Apr 2029 | 426 |
| NCT06682988Fallopian Tube Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | AbbVie | Jul 2026 | 110 |
| NCT06390995Ovarian Neoplasms · Japan | 2 | Active, not recruiting | Takeda | Apr 16, 2025 | 28 |
| NCT05622890Carcinoma, Ovarian Epithelial · China | 3 | UNKNOWN | Huadong Medicine | Apr 30, 2023 | 35 |
| NCT05445778Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Apr 2027 | 520 |
| NCT05456685Fallopian Tube Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | AbbVie | Nov 2026 | 125 |
| NCT05041257Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Completed | AbbVie | Dec 12, 2024 | 79 |
| NCT04296890Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more | 3 | Completed | AbbVie | Nov 16, 2021 | 106 |
| NCT04274426Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma · Germany | 2 | Active, not recruiting | AGO Research | Dec 3, 2025 | 136 |
| NCT04209855Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more | 3 | Completed | AbbVie | Mar 6, 2023 | 453 |
| NCT02631876Carcinoma, Ovarian Epithelial · United States, Belgium, Bosnia and Herzegovina and more | 3 | Completed | AbbVie | Jan 2019 | 366 |
| NCT02606305Carcinoma, Ovarian Epithelial · United States, Belgium, Canada and more | 2 | Completed | AbbVie | Mar 12, 2021 | 264 |
| NCT01609556Neoplasms · United States, Canada | 1 | Completed | AbbVie | Mar 19, 2018 | 206 |
How it is read
Names in the registry
- “Mirvetuximab Soravtansine”, 8 entries
- “Mirvetuximab soravtansine”, 5 entries
- “TAK-853”, 1 entry
- “Mirvetuximab soravtansine plus Bevacizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Ovarian Epithelial, 6 studies
- Ovarian Neoplasms, 5 studies
- Fallopian Tube Neoplasms, 2 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.